Literature DB >> 19930411

How much does international normalized ratio monitoring cost during oral anticoagulation with a vitamin K antagonist? A systematic review.

S Chambers1, S Chadda, J M Plumb.   

Abstract

Next-generation oral anticoagulants offer the potential for effective prevention and treatment of thrombosis without the need for repeated monitoring of the international normalized ratio (INR). This systematic review evaluated the costs associated with INR monitoring tests performed as part of the standard management of oral anticoagulation with vitamin K antagonists. Studies published in or after 1990 reporting the costs of INR monitoring were identified from bibliographic databases and manual searches of reference lists. Cost data were extracted and inflated to the year 2006 before purchasing power parity conversion to US dollars. A total of 29 studies reported the cost of one INR test, which was shown to range from $6.19 to $145.70. Cost estimates were based on various combinations of direct medical costs, such as healthcare contacts, equipment, laboratory tests, clerical costs (postage and stationery), telephone calls, quality control, training/education and patient transportation, and indirect costs, such as time lost from work. In conclusion, the cost of INR monitoring varied substantially between studies depending on the monitoring modality and setting, and the cost categories included. When selecting a published estimate, healthcare decision makers should ensure that the chosen estimate reflects local service provision as closely as possible.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19930411     DOI: 10.1111/j.1751-553X.2009.01205.x

Source DB:  PubMed          Journal:  Int J Lab Hematol        ISSN: 1751-5521            Impact factor:   2.877


  8 in total

1.  Echo-based screening of rheumatic heart disease in children: a cost-effectiveness Markov model.

Authors:  Justin P Zachariah; Mihail Samnaliev
Journal:  J Med Econ       Date:  2015-02-09       Impact factor: 2.448

Review 2.  Developing a Conversation Aid to Support Shared Decision Making: Reflections on Designing Anticoagulation Choice.

Authors:  Claudia L Zeballos-Palacios; Ian G Hargraves; Peter A Noseworthy; Megan E Branda; Marleen Kunneman; Bruce Burnett; Michael R Gionfriddo; Christopher J McLeod; Haeshik Gorr; Juan Pablo Brito; Victor M Montori
Journal:  Mayo Clin Proc       Date:  2019-01-11       Impact factor: 7.616

3.  Novel Oral Anticoagulants for Venous Thromboembolism with Special Emphasis on Risk of Hemorrhagic Complications and Reversal Agents.

Authors:  Zaheer Ahmed; Seemeen Hassan; Gary A Salzman
Journal:  Curr Drug ther       Date:  2016-04

4.  Clinical evaluation of whole blood prothrombin time (PT) and international normalized ratio (INR) using a Laser Speckle Rheology sensor.

Authors:  Markandey M Tripathi; Satoru Egawa; Alexandra G Wirth; Diane M Tshikudi; Elizabeth M Van Cott; Seemantini K Nadkarni
Journal:  Sci Rep       Date:  2017-08-23       Impact factor: 4.379

5.  Cost-Effective Modeling of Thromboembolic Chemoprophylaxis for Total Ankle Arthroplasty.

Authors:  Brandon J Martinazzi; Gregory J Kirchner; Christopher M Stauch; F Jeffrey Lorenz; Kristen M Manto; Vincenzo Bonaddio; Zachary Koroneos; Michael C Aynardi
Journal:  Foot Ankle Int       Date:  2022-07-28       Impact factor: 3.569

Review 6.  Oral anticoagulation to reduce risk of stroke in patients with atrial fibrillation: current and future therapies.

Authors:  Alpesh Amin
Journal:  Clin Interv Aging       Date:  2013-01-22       Impact factor: 4.458

7.  Cost-effectiveness of edoxaban compared to warfarin for the treatment and secondary prevention of venous thromboembolism in the UK.

Authors:  Emilie Clay; Aurélien Jamotte; Peter Verhamme; Alexander T Cohen; Ben A Van Hout; Pearl Gumbs
Journal:  J Mark Access Health Policy       Date:  2018-07-17

8.  Cost Conversations About Anticoagulation Between Patients With Atrial Fibrillation and Their Clinicians: A Secondary Analysis of a Randomized Clinical Trial.

Authors:  Celia C Kamath; Rachel Giblon; Marlene Kunneman; Alexander I Lee; Megan E Branda; Ian G Hargraves; Angela L Sivly; Fernanda Bellolio; Elizabeth A Jackson; Bruce Burnett; Haeshik Gorr; Victor D Torres Roldan; Gabriella Spencer-Bonilla; Nilay D Shah; Peter A Noseworthy; Victor M Montori; Juan P Brito
Journal:  JAMA Netw Open       Date:  2021-07-01
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.